International medical device companies and others doing business in China are becomingly increasingly cautious about the government's broadening antitrust and corruption investigations. Reuters reports that they're bringing in attorneys to make sure their operations comply with China's 5-year-old anti-monopoly law, a measure that officials have used in earnest to investigate GlaxoSmithKline ($GSK), among others, in recent weeks. An executive from a foreign-listed medical devicemaker told Reuters that he has spent weeks visiting all of his company's offices in China to make sure there was no "grey zone" business involving third-party sales agents. Others have added more internal audits to make sure they comply with the rules. Story